Skip to main content

Advertisement

SpringerLink
Log in

Paraoxonase and arylesterase levels in rheumatoid arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

It was reported that lipid peroxidation (LPO) products increase in rheumatoid arthritis (RA) patients and increased LPO products reduce many antioxidants. Lipid hydroperoxides (LOOHs) are byproduct of LPO. Paraoxonase (PON), arylesterase (ARE), free sulfhydryl (SH) groups, and ceruloplasmin (CP) are enzymes or proteins with antioxidant characteristics. This study aims to determine the levels of LOOHs and SH, and the activities of PON1, ARE, and CP in RA patients. The study included 47 active RA cases and 23 healthy volunteers. The levels of LOOHs and SH, and the activities of PON1, ARE, and CP were determined using appropriate methods. Student’s t test and Spearman’s correlation analysis methods were employed in the statistical evaluation. The level of LOOHs was found to be higher (p<0.001), while the level of SH and the activities of PON1, ARE, and CP were found to be lower (p<0.001, <0.001, <0.01, and <0.01, respectively) in the RA patient group when compared with the control group. There was a negative correlation between the level of LOOHs and the activity of PON1 in the patient group (r=−0.420 and p<0.01). The results of our study indicate increased oxidant and decreased antioxidant presence in RA patients. PON1 and ARE are known to have antiatherosclerotic effects in addition to their antioxidant characteristics. As the decrease in these antioxidants, resulting from increased oxidative stress in RA patients, development of atherosclerosis besides tissue injury seems inevitable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Fox DA (2005) Etiology and pathogenesis of rheumatoid arthritis. In: Koopman WJ, Moreland LW (eds) Arthritis and allied conditions: a textbook of rheumatology, 15th edn. Lippincot Williams and Wilkins, Philadelphia, pp 1089–1115

    Google Scholar 

  2. Jasin HE (2005) Mechanisms of tissue damage in rheumatoid arthritis. In: Koopman WJ, Moreland LW (eds) Arthritis and allied conditions: a textbook of rheumatology, 15th edn. Lippincot Williams and Wilkins, Philadelphia, pp 1141–1164

    Google Scholar 

  3. Griffiths HR, Lunec J (1996) The C1q binding activity of IgG is modified in vitro by reactive oxygen species: implications for rheumatoid arthritis. FEBS Lett 388(2–3):161–164

    Article  PubMed  CAS  Google Scholar 

  4. Nurcombe HL, Bucknall RC, Edwards SW (1991) Activation of the neutrophil myeloperoxidase-H2O2 system by synovial fluid isolated from patients with rheumatoid arthritis. Ann Rheum Dis 50(4):237–242

    PubMed  CAS  Google Scholar 

  5. Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(24):2957–2963

    Article  PubMed  Google Scholar 

  6. Zwerina J, Redlich K, Schett G, Smolen JS (2005) Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci 1051:716–729

    Article  PubMed  CAS  Google Scholar 

  7. Ridderstad A, Abedi-Valugerdi M, Moller E (1991) Cytokines in rheumatoid arthritis. Ann Med 23(3):219–223

    PubMed  CAS  Google Scholar 

  8. Miesel R, Murphy MP, Kroger H (1996) Enhanced mitochondrial radical production in patients which rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic Res 25(2):161–169

    PubMed  CAS  Google Scholar 

  9. Jaswal S, Mehta HC, Sood AK, Kaur J (2003) Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin Chim Acta 338(1–2):123–129

    Article  PubMed  CAS  Google Scholar 

  10. Jira W, Spiteller G, Richter A (1997) Increased levels of lipid oxidation products in low density lipoproteins of patients suffering from rheumatoid arthritis. Chem Phys Lipids 87(1):81–89

    Article  PubMed  CAS  Google Scholar 

  11. Frears ER, Zhang Z, Blake DR, O’Connell JP, Wiynard PG (1996) Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 381(1–2):21–24

    Article  PubMed  CAS  Google Scholar 

  12. Ozturk HS, Cimen MY, Cimen OB, Kacmaz M, Durak I (1999) Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int 19:35–37

    Article  PubMed  CAS  Google Scholar 

  13. McKeown MJ, Hall ND, Corvalan JR (1984) Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis. Clin Exp Immunol 56(3):607–613

    PubMed  CAS  Google Scholar 

  14. Banford JC, Brown DH, Hazelton RA, McNeil CJ, Smith WE, Stturrock RD (1982) Altered thiol status in patients with rheumatoid arthritis. Rheumatol Int 2(3):107–111

    Article  PubMed  CAS  Google Scholar 

  15. Goldstein IM, Kaplan HB, Edelson HS, Weissmann G (1979) Ceruloplasmin. A scavenger of superoxide anion radicals. J Biol Chem 254(10):4040–4045

    PubMed  CAS  Google Scholar 

  16. Rafter GW (1994) Plasma thiols, copper and rheumatoid arthritis. Med Hypotheses 43(1):59–61

    Article  PubMed  CAS  Google Scholar 

  17. Kiziltunc A, Cogagil S, Cerrahoglu L (1998) Carnitine and antioxidants levels in patients with rheumatoid arthritis. Scand J Rheumatol 27(6):441–445

    Article  PubMed  CAS  Google Scholar 

  18. Dogan P, Tanrikulu G, Soyuer U, Kose K (1994) Oxidative enzymes of polymorphonuclear leucocytes and plasma fibrinogen, ceruloplasmin, and copper levels in Behcet’s disease. Clin Biochem 27(5):413–418

    Article  PubMed  CAS  Google Scholar 

  19. Gutteridge JM, Winyard PG, Blake DR, Lunec J, Brailsford S, Halliwell B (1985) The behaviour of caeruloplasmin in stored human extracellular fluids in relation to ferroxidase II activity, lipid peroxidation and phenanthroline-detectable copper. Biochem J 230(2):517–523

    PubMed  CAS  Google Scholar 

  20. Mackness B, Durrington PN, Mackness MI (1998) Human serum paraoxonase. Gen Pharmacol 31(3):329–336

    Article  PubMed  CAS  Google Scholar 

  21. Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21(4):473–480

    PubMed  CAS  Google Scholar 

  22. Mackness MI, Mackness B, Durrington PN (2003) Paraoxonase and coronary heart disease. Atheroscler Suppl 3(4):49–55

    Article  Google Scholar 

  23. Arnet FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324

    Google Scholar 

  24. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77

    Article  PubMed  CAS  Google Scholar 

  25. Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B (1993) Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 121(2):257–262

    PubMed  CAS  Google Scholar 

  26. La Du BN, Eckerson HW (1984) The polymorphic paraoxonase/arylesterase isozymes of human serum. Fed Proc 43:2338–2341

    PubMed  Google Scholar 

  27. Sunderman FW, Nomoto S (1970) Measurement of human serum ceruloplasmin by its p-phenylenediamine oxidase activity. Clin Chem 16(11):903–910

    PubMed  CAS  Google Scholar 

  28. Erel O (1998) Automated measurement of serum ferroxidase activity. Clin Chem 44(11):2313–2319

    PubMed  CAS  Google Scholar 

  29. Gorog P, Kotak DC, Kovacs IB (1991) Simple and specific test for measuring lipid peroxides in plasma. J Clin Pathol 44(9):765–767

    PubMed  CAS  Google Scholar 

  30. Pinals RS, Masi AT, Larsen RA (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24(10):1308–1315

    PubMed  CAS  Google Scholar 

  31. Symmons DP, Jones MA, Scott DL, Prior P (1998) Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25:1072–1077

    PubMed  CAS  Google Scholar 

  32. Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46(4):862–873

    Article  PubMed  Google Scholar 

  33. Gutteridge JM (1985) Inhibition of the Fenton reaction by the protein caeruloplasmin and other copper complexes. Assessment of ferroxidase and radical scavenging activities. Chem Biol Interact 56(1):113–120

    Article  PubMed  CAS  Google Scholar 

  34. Louro MO, Cocho JA, Mera A, Tutor JV (2000) Immunochemical and enzymatic study of ceruloplasmin in rheumatoid arthritis. J Trace Elem Med Biol 14(3):174–178

    Article  PubMed  CAS  Google Scholar 

  35. Gambhir JK, Lali P, Jain AK (1997) Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin Biochem 30(4):351–355

    Article  PubMed  CAS  Google Scholar 

  36. Hall ND, Maslen CL, Blake DR (1984) The oxidation of serum sulph-hydryl groups by hydrogen peroxide secreted by stimulated phagocytic cells in rheumatoid arthritis. Rheumatol Int 4(1):35–38

    Article  PubMed  CAS  Google Scholar 

  37. Hall ND, Blake DR, Bacon PA (1982) Serum sulphydryl levels in early synovitis. J Rheumatol 9(4):593–596

    PubMed  CAS  Google Scholar 

  38. Giustarini D, Lorenzini S, Rossi R, Chindamo D, Di Simplicio P, Marcolongo R (2005) Altered thiol pattern in plasma of subjects affected by rheumatoid arthritis. Clin Exp Rheumatol 23(2):205–212

    PubMed  CAS  Google Scholar 

  39. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S et al (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394(6690):284–287

    Article  PubMed  CAS  Google Scholar 

  40. Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y, Nishiya K et al (2003) Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 72(25):2877–2885

    Article  PubMed  CAS  Google Scholar 

  41. Baskol G, Demir H, Baskol M, Kilic E, Ates F, Kocer D et al (2005) Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem 38(10):951–955

    Article  PubMed  CAS  Google Scholar 

  42. Maury CP, Junge W, Teppo AM (1984) Serum esterase activity in reactive systemic amyloidosis and its relation to amyloid A degrading activity. J Lab Clin Med 104(5):761–766

    PubMed  CAS  Google Scholar 

  43. Feingold KR, Menon RA, Moser AH, Grunfeld C (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139(2):307–315

    Article  PubMed  CAS  Google Scholar 

  44. Kumon Y, Nakauchi Y, Suehiro T, Shiinoki T, Tanimoto N, Inoue M et al (2002) Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells. Amyloid 9(3):160–164

    PubMed  CAS  Google Scholar 

  45. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M et al (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18(10):1617–1624

    PubMed  CAS  Google Scholar 

  46. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL et al (1999) Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26:892–904

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Faculty of Medicine, University of Firat, Firat Tip Merkezi, İc Hastaliklari AD, Romatoloji BD, Elazig, 23119, Turkey

    A. Isik, S. S. Koca & A. Yildirim

  2. Department of Biochemistry, Faculty of Medicine, University of Firat, Elazig, Turkey

    B. Ustundag

  3. Department of Biochemistry, Faculty of Medicine, University of Harran, Sanliurfa, Turkey

    H. Celik

Authors
  1. A. Isik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. S. Koca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Ustundag
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Yildirim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. S. Koca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Isik, A., Koca, S.S., Ustundag, B. et al. Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin Rheumatol 26, 342–348 (2007). https://doi.org/10.1007/s10067-006-0300-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0300-8

Keywords

Search

Navigation